Cytostatic agents breast cancer

An unusual case of rapidly fatal renal failure reported in 1993 could reflect an interaction between tamoxifen and one or more cytostatic agents, with mitomycin C a prime suspect in a series of breast cancer patients some 10% of those treated both with tamoxifen and a cytostatic agent developed abnormal renal function, progressing towards various stages of hemolytic-uremic syndrome (118). 

Pharmacology V., together with vincristine and the semisynthetic vindesine (deacetyl-V.-23-amide), is now established in modem cytostatic therapy (i.v.). It acts in the same was as colchicine (see phenethyltetra-hydroisoquinoline alkaloids) as an inhibitor of mitosis and arrests the metaphase by binding to microtubular proteins. In addition, V. inhibits DNA polymerase and thus also DNA biosynthesis. In combination with other cytostatic agents it is used in therapy for (non)-Hodgkin s lymphomas, testicular, breast, and lung cancer. ... 

---